# Aditxt, Inc. (ADTX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ADTX
## Company Profile
- Ticker: ADTX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 0.0031 USD
- Market cap: 89588.1258 USD
- Last updated: 2026-10-05
## Business Overview
### Immune Health Technology Company
Aditxt develops and assembles technologies for immune monitoring, immune modulation, and precision diagnostics. Its business is organized through subsidiaries and licensed platforms rather than a single therapeutic franchise.
### Adimune Immune Modulation
Adimune holds rights to nucleic-acid-based technology intended to retrain immune responses. The platform is being explored for autoimmune and other immune-mediated diseases through preclinical and development programs.
### AditxtScore Immune Monitoring
AditxtScore is designed to provide a personalized profile of immune status. The technology evaluates antibody and cellular responses and can support monitoring of infection, vaccination, and immune health.
### Pearsanta Precision Diagnostics
Pearsanta is developing mitochondrial-DNA-based biomarkers for diseases including prostate cancer and endometriosis. Earlier discovery work has also identified potential biomarker signatures in additional cancers.
### Subsidiary and Transaction Model
Aditxt forms or acquires subsidiaries around distinct technologies and seeks outside financing, partnerships, and acquisitions to expand them. This structure creates multiple development tracks but also makes execution dependent on transaction completion and capital availability.
## Why The Stock Is Moving

As of Oct 5, 2026, ADTX closed down 3.13% at $0.0031. No new same-company headline was identified in the current news window.

## Recent News
- 2023-10-06 12:00 EST — [Aditxt, Inc. to Present at 8th Annual Dawson James Conference](https://biopharmsignal.com/news/ADTX/aditxt-inc-to-present-at-8th-annual-dawson-james-conference-43bb8685) — Source: Aditxt, Inc.